Vildagliptin‐Induced Bullous Pemphigoid: A Retrospective Cohort Study
Abstract
Bullous pemphigoid (BP) is a common autoimmune blistering disease associated with medications, particularly dipeptidyl peptidase-4 inhibitors such as vildagliptin, funded in New Zealand since 2018. We conducted a retrospective single-centre study of histologically confirmed BP cases between 2018 and 2023. Of 49 patients identified, 15 (30.6%) had vildagliptin-induced BP. Māori patients were over-represented in this subgroup. The mean time to BP onset after vildagliptin initiation was 388 days. Non-vildagliptin BP was more likely to require systemic immunosuppression. Vildagliptin-induced BP represents a common and under-recognised clinical entity in New Zealand.
Fields of Study & Subjects
Autoimmune Bullous Skin Diseases
Urticaria and Related Conditions
Coagulation
Bradykinin
Polyphosphates
and Angioedema
Publication details
- Journal / source
- Australasian Journal of Dermatology
- Volume
- 67
- Issue
- 2
- Pages
- e116–e120
- Publication date
- 6 January 2026
- Language
- EN